Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2017

01-05-2017 | Epidemiology

Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities

Authors: Carol A. Parise, Vincent Caggiano

Published in: Breast Cancer Research and Treatment | Issue 1/2017

Login to get access

Abstract

Purpose

The ER-/PR-/HER2- or triple-negative (TNBC) subtype is more prevalent among women who are young, black, Hispanic, and of lower SES. The purpose of this study is to determine if young age and low SES are associated with TNBC within four mutually exclusive race/ethnicities.

Methods

The study identified 19,283 cases of TNBC and 89,089 of ER+/PR+/HER2- from the California Cancer Registry. Logistic regression analyses were conducted separately for whites, blacks, Hispanics, and Asian/Pacific Islanders (API) to compute the adjusted odds ratios (OR) for age and SES for the TNBC versus the ER+/PR+/HER2- subtype.

Results

White (OR=1.37;1.23-1.53) and Hispanic and women (OR=1.35;1.17-1.56) 30–39 had increased odds of the TNBC when compared with women 50–59 of the same race/ethnicity. Black women under 40 had the same odds, and black women 40–49 had lower odds of the TNBC as black women 50–59. White, black, and Hispanic women 70 and older had decreased or the same odds of the TNBC as 50 to 59-year-old women. API women had a similar risk of TNBC at all ages. Lower SES was associated with increased risk of TNBC only for white and Hispanic women. The odds of TNBC were no worse for API women with lower SES than API women with higher SES. SES was not statistically significant for black women.

Conclusions

When assessing the odds of TNBC within a single race/ethnicity, young age and low SES are risk factors only for white and Hispanic women, but not for black and API women.
Literature
1.
2.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752CrossRefPubMed
3.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874CrossRefPubMedPubMedCentral
4.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502CrossRefPubMed
5.
Campleman S, Curtis R (2004) Demographic aspects of breast cancer incidence and mortality in California. In: Morris C, Kwong SL (eds) Breast Cancer in California, 2003, vol July. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, pp 1988–1999
6.
Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast Journal 15(6):593–602. doi:10.​1111/​j.​1524-4741.​2009.​00822.​x CrossRefPubMed
7.
Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O’Regan R, Torres MA, Meisel JL (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161(2):279–287. doi:10.​1007/​s10549-016-4059-6 CrossRefPubMed
8.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109(9):1721–1728CrossRefPubMed
9.
Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V (2008) The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999-2004. Cancer 112(4):737–747CrossRefPubMed
10.
11.
12.
Fritz AG (2000) International classification of diseases for oncology : ICD-O, 3rd edn. World Health Organization, Geneva, Geneva
13.
Cancer reporting in California: Abstracting and coding procedures for hospitals. California cancer reporting system standards, Volume I (2008). California Department of Public, Cancer Surveillance and Research Branch, Sacramento, CA
14.
15.
Bauer KR, Brown M, Creech C, Schlag NC, Caggiano V (2007) Data quality assessment of HER2 in the Sacramento Region of the California Cancer Registry. Journal of Registry Management 34(1):4–7
16.
17.
Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12(8):703–711CrossRefPubMed
18.
Clarke CA, Glaser SL, Keegan TH, Stroup A (2005) Neighborhood socioeconomic status and Hodgkin’s lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev 14(6):1441–1447CrossRefPubMed
19.
Parikh-Patel A, Bates JH, Campleman S (2006) Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988-2000. Cancer 107(5 Suppl):1189–1195CrossRefPubMed
20.
Zell JA, Rhee JM, Ziogas A, Lipkin SM, Anton-Culver H (2007) Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev 16(3):546–552CrossRefPubMed
21.
Ou SH, Zell JA, Ziogas A, Anton-Culver H (2008) Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer 112(9):2011–2020CrossRefPubMed
22.
Yin D, Morris C, Allen M, Cress R, Bates J, Liu L (2010) Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups? Cancer Causes Control 21(10):1721–1730CrossRefPubMedPubMedCentral
23.
Telli ML, Chang ET, Kurian AW, Keegan TH, McClure LA, Lichtensztajn D, Ford JM, Gomez SL (2011) Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat 127(2):471–478. doi:10.​1007/​s10549-010-1173-8 CrossRefPubMed
24.
Parise CA, Bauer KR, Caggiano V (2012) Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California. Cancer 118(9):2516–2524CrossRefPubMed
25.
IBM SPSS Statistics for Windows (2012). vol 21.0. IBM Corp, Armonk NY
26.
Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O’Regan RM, Gabram SG, Eley JW (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta. GA. Breast Cancer Res Treat 113(2):357–370. doi:10.​1007/​s10549-008-9926-3 CrossRefPubMed
27.
28.
29.
Amirikia KC, Mills P, Bush J, Newman LA (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations. Cancer 117(12):2747–2753CrossRefPubMedPubMedCentral
30.
31.
Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, Blanchard RA, Lee JC, King TC, Rosenberg CL (2009) Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 11(2):R18. doi:10.​1186/​bcr2242 CrossRefPubMedPubMedCentral
32.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. doi:10.​1172/​JCI45014 CrossRefPubMedPubMedCentral
33.
Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30(15):1879–1887. doi:10.​1200/​JCO.​2011.​38.​2010 CrossRefPubMed
34.
35.
36.
37.
Gordon NH (1995) Association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemiol 142(8):796–803CrossRefPubMed
38.
Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, Goodman MT, Lynch CF, Schwartz SM, Chen VW, Bernstein L, Gomez SL, Graff JJ, Lin CC, Johnson NJ, Edwards BK (2009) Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control 20(4):417–435. doi:10.​1007/​s10552-008-9256-0 CrossRefPubMed
39.
Taylor A, Cheng KK (2003) Social deprivation and breast cancer. J Public Health Med 25(3):228–233CrossRefPubMed
40.
Izquierdo JN, Schoenbach VJ (2000) The potential and limitations of data from population-based state cancer registries. Am J Public Health 90(5):695–698CrossRefPubMedPubMedCentral
41.
42.
43.
44.
45.
Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103(6):470–477CrossRefPubMedPubMedCentral
46.
47.
Chen L, Li CI, Tang MT, Porter P, Hill DA, Wiggins CL, Cook LS (2016) Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women. Cancer Epidemiol Biomarkers Prev 25(9):1297–1304. doi:10.​1158/​1055-9965.​EPI-15-1104 CrossRefPubMed
48.
Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282–4288. doi:10.​1200/​JCO.​2008.​16.​6231 CrossRefPubMed
49.
Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, Wenstrup RJ, Sandbach JF (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118(11):2787–2795. doi:10.​1002/​cncr.​26576 CrossRefPubMed
50.
Churpek JE, Walsh T, Zheng Y, Moton Z, Thornton AM, Lee MK, Casadei S, Watts A, Neistadt B, Churpek MM, Huo D, Zvosec C, Liu F, Niu Q, Marquez R, Zhang J, Fackenthal J, King MC, Olopade OI (2015) Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat 149(1):31–39. doi:10.​1007/​s10549-014-3195-0 CrossRefPubMed
51.
Zeichner SB, Stanislaw C, Meisel JL (2016) Prevention and Screening in Hereditary Breast and Ovarian Cancer. Oncology (Williston Park) 30 (10)
Metadata
Title
Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities
Authors
Carol A. Parise
Vincent Caggiano
Publication date
01-05-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4159-y

Other articles of this Issue 1/2017

Breast Cancer Research and Treatment 1/2017 Go to the issue

Erratum

Erratum to: Diagnostic performance of tomosynthesis and breast ultrasonography in women with dense breasts: a prospective comparison study

Preclinical study

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data

Clinical trial

Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer

Review

Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis

Review

A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy

Epidemiology

A polygenic risk score for breast cancer risk in a Taiwanese population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits